"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development Overview
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEW
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEW
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEW
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MORE
"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.
VIEW ROLES
The implementation of the EU HTA Regulation represents a turning point for health technology assessments (HTA), impacting market access strategies and launch preparations at global, regional and national level.
Tap into IQVIA’s unparalleled combination of expertise and skills, to maximise the benefits of the new Joint Clinical Assessments (JCA) process for your assets. With IQVIA EU HTA Solutions you have one partner by your side to support you on your JCA journey – end-to-end, and EU-wide.
Stay up-to-date on the latest policy news and methodological guidance published, EU Member State preparations for EU HTA, key conferences and more with our quarterly EU HTA Newsletter. Click on the button if you are interested in this offering.
Client need: Guidance to optimize teams, resources, and internal processes ahead of their first Joint Clinical Assessment (JCA) submission in 2025
Solution: Conducted EU HTA readiness assessment and peer benchmarking to identify existing gaps, and co-created comprehensive guidance for the operationalization of JCA together with cross-functional client teams
Results: Established new ways of working at global, regional, and local level, to meet JCA requirements and successfully execute their first Joint Clinical Assessment (JCA) submission
Client need: (i) Tool to define optimal approach for early HTA scientific advice (ESA), considering Joint Scientific Consultation (JSC), parallel EMA-JSC advice, and local ESA opportunities; (ii) end-to-end ESA support for pipeline asset
Solution: (i) Developed a decision-making tool based on uncertainty in HTA approach, risk associated with joint/parallel engagement, importance of markets, and timing requirements vs. asset approval timeline; (ii) Used the tool to assess ESA opportunity for target pipeline asset, and supported application, briefing book development, strategic review of advice, and developed recommendations
Results: (i) Playbook to facilitate ESA preparations; (ii) recommendations to refine the pipeline asset’s trial protocol
Client need: PICO prediction for two oncology pipeline assets, and strategic recommendations to optimize evidence generation
Solution: Assessed analogues and simulated the scoping process in line with the latest JCA guidance documents to predict likely PICOs; mapped planned evidence generation activities against PICOs to identify any gaps
Results: Asset-specific recommendations for evidence generation strategy, to optimise data package based on the anticipated PICOs
Client need: Development of JCA strategy, JCA dossiers and objection handler for two oncology assets, in addition to indirect treatment comparison (ITC) feasibility assessment and analyses
Solution: Define JCA strategy based on predicted PICOs, evidence package and anticipated label, and draft JCA dossier; assess ITC feasibility, define strategy, and conduct ITC analyses in line with the published JCA guidance; following JCA scope confirmation, finalise the dossiers in line with refined JCA strategy; provide post-submission support and finalise objection handler to aid local HTA communication and submissions
Results: Support currently ongoing
Client need: National dossier development for the client’s first two assets eligible for Joint Clinical Assessment (JCA), including strategic advice on relevant analyses for local HTA success and mitigation strategies; recommendation on best practices to incorporate local needs into regional and global JCA preparations
Solution: Planning and development of the ‘delta’ dossiers; strategic recommendations to shape new internal JCA processes to ensure local evidence requirements and dossier preparations are optimally aligned
Results: Support currently ongoing
Market Access Insights provides access to HTA, reimbursement, regulatory, clinical trial, and pricing information so that you can make more informed market access decisions.
Access clearer, more compelling support to demonstrate the value of your product.
Understand how payers, providers, and patients define value, and accelerate market access for new and innovative products.
Learn how unparalleled data, domain expertise, and technologies enable AI-powered solutions that are purpose-built for healthcare.
Navigate complex regulatory requirements with expert insights and bring transparency, efficiency and predictability to your regulatory affairs strategy.
Strengthen your portfolio by making more informed decisions and prepare for the impact of new research discoveries.
